The myth of the second remission of acute leukemia in the adult.
about
CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemiaTreating relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia: liposome-encapsulated vincristineCD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemiaChimeric antigen receptor T cells for sustained remissions in leukemiaInterpreting outcome data in hematological malignancies: a paradigm for clinical studiesInterpreting outcome data in hematopoietic cell transplantation for leukemia: tackling common biases.Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).Survival of hematological patients after discharge from the intensive care unit: a prospective observational study.Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.Risk factors for outcomes after unrelated cord blood transplantation for adults with acute lymphoblastic leukemia: a report on behalf of Eurocord and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.Conditioning intensity in middle-aged patients with AML in first CR: no advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT.Rational Combinations of Targeted Agents in AMLReduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.AML sensitivity to YM155 is modulated through AKT and Mcl-1.Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia.Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysisClinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors.Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG.Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 studyPre-clinical evaluation of tyrosine kinase inhibitors for treatment of acute leukemia.Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies.Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.Should persons with acute myeloid leukemia have a transplant in first remission?Allogeneic hematopoietic cell transplantation for acute myeloid leukemia during first complete remission: a clinical perspective.Targeting novel signaling pathways for resistant acute myeloid leukemia.The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.Blinatumomab: A First-in-Class Bispecific T-Cell Engager for Precursor B-Cell Acute Lymphoblastic Leukemia.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission.Molecular and genetic alterations associated with therapy resistance and relapse of acute myeloid leukemia.CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.What Is the Optimal Induction Therapy for Younger Fit Patients With AML?Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis.The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.Treatment of Relapsed/Refractory Acute Myeloid Leukemia.
P2860
Q26783433-D3553063-3CAF-4613-8090-1056B44170A4Q26785828-4DF7E209-DD8E-4AFA-A435-085326EBB218Q27000078-E5D1B0EF-C9D5-4192-A080-A8EBA5304816Q28084879-48B322FA-E403-4F82-8F49-27C5FE3D2EF0Q29617588-02BE1264-6053-4DAE-89E6-575258DF5564Q30658847-2BF1CF43-70D1-4B06-AE61-7B832C8C598AQ30884173-FDC49152-CD85-497D-B027-3F887429E1FFQ33422405-ADC74CA1-65A1-468B-A4D8-93A431E96A74Q33752015-BE3D035B-582B-43A8-8D91-61E8B8BAC0EFQ33840360-038690B3-27B7-43B9-839E-62532E1D097AQ34172042-BA63D3E8-1A60-4BB9-BF17-504ED023418EQ35199893-38AD2A25-2F09-473E-A30B-4C133243B105Q35647641-F747ED9C-491A-4F98-B331-E304E5197584Q35750491-D75BFDA7-71EB-492E-95A8-7093BF5C6669Q35800814-546F0462-A081-4C9F-BE7D-61CD2CA9687EQ35983805-3F936FF3-0956-4AAD-9853-5571C9C22F2EQ36110355-83255E6C-AEA5-4D65-9E8A-33C905805F69Q36219592-A99726BA-2433-406F-9E32-39A850F1F673Q36545348-5E5A9909-676D-400D-ACA3-1FF2337906E4Q36557537-FBF42ED1-CF2A-45A0-8DAF-F69CD3114A1AQ37129564-0F3C596D-EF7B-47BA-862D-F351F3AF1982Q37217432-0E78D46F-7682-4ED7-97D7-04841E32CF6EQ37263151-95AF5D37-56DC-4B04-BF45-C91D72C40257Q37582854-BD035007-1AC8-4EE0-B593-EC84BE753CE0Q37615772-CC3A1203-7F04-4556-B1F3-D2A7CF29B5C9Q37697847-D7EA665D-9DDA-4AB0-B630-5A2A53ADC13AQ38204207-781FBF56-FEDF-435D-86BC-E6079FDBCF4CQ38248427-1F0C8070-C791-42F7-ACD1-C4319BB6587DQ38297507-61C57FC7-9C48-41AC-B943-78AC40FE9271Q38375425-F7921CB1-A263-4F1F-81A8-1F7A057C526FQ38515225-56CCFF63-E0F8-4DE2-95DF-1F3E6A92BAA3Q38664735-3B923859-AFD0-4252-A346-D0DAC2E87445Q38748924-88749F76-B155-4074-9CA5-A0BE137DCAC3Q38755213-4A39F1F8-291E-4CAD-8423-31E0EBB46849Q38813257-83343A86-E3DA-4A42-872A-11BA0863AB69Q38840423-9C425F20-76E2-41C3-80E9-7F547B9A23C6Q38913554-EC835C19-39D4-4A85-BFC7-012822262EA0Q39002065-0CFEB690-D7D0-43E1-B9B9-0A91AEBE3566Q39039017-887A396E-15D2-4EF7-9438-F5D1A9B97D7BQ39175665-C687E9E7-9D6B-4340-A166-E4D83CB2951E
P2860
The myth of the second remission of acute leukemia in the adult.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The myth of the second remission of acute leukemia in the adult.
@ast
The myth of the second remission of acute leukemia in the adult.
@en
type
label
The myth of the second remission of acute leukemia in the adult.
@ast
The myth of the second remission of acute leukemia in the adult.
@en
prefLabel
The myth of the second remission of acute leukemia in the adult.
@ast
The myth of the second remission of acute leukemia in the adult.
@en
P2860
P1433
P1476
The myth of the second remission of acute leukemia in the adult.
@en
P2093
Jacob M Rowe
Stephen J Forman
P2860
P304
P356
10.1182/BLOOD-2012-08-234492
P407
P577
2012-12-14T00:00:00Z